Managers / Q1 2020 · view latest →
Krensavage Asset Management, LLC
CIK 0001609251 · 610 FIFTH AVENUE, SUITE 301, NEW YORK, NY, 10020 · 212-888-1582
Summary
Krensavage Asset Management, LLC reported $311M in U.S.-listed holdings across 13 positions for Q1 2020.
Its largest position, UTHR, represents 16.5% of the portfolio.
Compared with Q4 2019, the fund opened 1 new position and exited 0.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 90.4% · $281M
- Other · 9.6% · $30M
Quarter-over-Quarter Changes full breakdown →
vs Q4 2019 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| CHANGE HEALTHCARE INC | NEW | +3.6K | 3.6K | +$36,000 | $36,000 |
| ALXNALEXION PHARMACEUTICALS INC | ADDED | +148.6K | 462.1K | +$8M | $41M |
| TARO PHARMACEUTICAL INDUS | ADDED | +147.5K | 487.3K | −$59,000 | $30M |
| ENTAENANTA PHARMACEUTICALS INC | ADDED | +210.9K | 700.3K | +$6M | $36M |
| ALKSALKERMES PLC | ADDED | +262.6K | 1.17M | −$2M | $17M |
| UTHRUNITED THERAPEUTICS CORP | ADDED | +78.7K | 539.6K | +$11M | $51M |
| REGNREGENERON PHARMACEUTICALS | TRIMMED | −17.6K | 86.8K | +$3M | $42M |
| MCKMCKESSON CORP | TRIMMED | −36.0K | 218.3K | −$6M | $30M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q1 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | UTHRUNITED THERAPEUTICS CORPhistory → | COM | 16.46% | $51M | 539.6K |
| 2 | REGNREGENERON PHARMACEUTICALShistory → | COM | 13.64% | $42M | 86.8K |
| 3 | ALXNALEXION PHARMACEUTICALS INChistory → | COM | 13.35% | $41M | 462.1K |
| 4 | ENTAENANTA PHARMACEUTICALS INChistory → | COM | 11.58% | $36M | 700.3K |
| 5 | BIIBBIOGEN INChistory → | COM | 11.27% | $35M | 110.8K |
| 6 | TARO PHARMACEUTICAL INDUS | COM | 9.59% | $30M | 487.3K |
| 7 | MCKMCKESSON CORPhistory → | COM | 9.50% | $30M | 218.3K |
| 8 | ALKSALKERMES PLChistory → | COM | 5.42% | $17M | 1.17M |
| 9 | GILDGILEAD SCIENCES INChistory → | COM | 2.83% | $9M | 117.8K |
| 10 | RTI SURGICAL HDS INC | COM | 2.22% | $7M | 4.03M |
| 11 | INVACARE CORP | COM | 2.12% | $7M | 887.2K |
| 12 | ANABANAPTYSBIO INChistory → | COM | 2.02% | $6M | 443.9K |
| 13 | CHANGE HEALTHCARE INC | COM | 0.01% | $36,000 | 3.6K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $256M | 20 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $283M | 18 | Feb 18, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $235M | 17 | Nov 17, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $189M | 15 | Aug 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $181M | 14 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $169M | 12 | Feb 18, 2025 | RESTATEMENT | changes · EDGAR ↗ |
| Q3 2024 | $178M | 13 | Nov 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $218M | 13 | Aug 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $226M | 12 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $282M | 12 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 12 | Nov 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $316M | 12 | Aug 11, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $329M | 12 | May 16, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $324M | 12 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $314M | 14 | Nov 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $302M | 14 | Aug 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $290M | 13 | May 17, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $288M | 10 | Feb 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $319M | 13 | Nov 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $295M | 13 | Aug 13, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $289M | 12 | May 18, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $342M | 12 | Feb 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $314M | 11 | Dec 8, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q2 2020 | $368M | 11 | Aug 20, 2020 | RESTATEMENT | changes · EDGAR ↗ |
| Q1 2020 | $311M | 13 | May 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $293M | 12 | Feb 18, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $260M | 10 | Nov 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $308M | 10 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $370M | 12 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.